Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

 
Note: The CAP along with their partners IASLC and AMP are committed to keeping this guideline up to date. The expert panel is currently working on the revision and expected publication is late 2017.

Background

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have developed an evidence-based guideline which establishes recommendations for EGFR and ALK testing, helping to guide targeted therapies.

The guideline was released on April 3, 2013, in Archives of Pathology & Laboratory Medicine, Journal of Thoracic Oncology, and The Journal of Molecular Diagnostics.

The guideline provides answers to these important clinical questions:

  • When should testing be performed?
  • How should EGFR testing be performed?
  • How should ALK testing be performed?
  • Should other genes be routinely tested in lung cancer?
  • How should molecular testing of lung cancer be implemented?

The implementation of the CAP/IASLC/AMP guideline will ensure a uniform approach to the molecular testing of lung cancer and will improve the effectiveness of lung cancer treatment for patients.

 

Feedback on Recommendations